Novo Nordisk is in search of offers greater than ever earlier than, the CEO of the Danish drugmaker stated in an interview with CNBC on Wednesday.
“If our ambition is to assist tons of of tens of millions of sufferers on the market, then we’d like not simply the very best, however the broadest pipeline on the planet,” stated Novo Nordisk CEO Mike Doustdar. “So let’s go and see who else principally has belongings which can be complementary to what we’ve. And we’re fairly lively with these [business development] talks and acquisitions, and you may see extra of these as effectively going ahead.”
Novo created the marketplace for GLP-1 weight reduction medication with its weekly photographs Ozempic and Wegovy. Extra not too long ago, the corporate has confronted issues from analysts about whether or not Novo’s pipeline is strong sufficient for it to stay a pacesetter within the more and more aggressive weight problems drug house.
Mike Doustdar, chief govt officer of Novo Nordisk A/S, throughout an interview in New York, US, on Wednesday, Feb. 11, 2026.
Michael Nagle | Bloomberg | Getty Photographs
Rival Eli Lilly has already overtaken Novo in market share for weekly GLP-1 photographs, although Novo has taken an early lead within the new class of GLP-1 tablets for weight reduction.
Doustdar stated he disagrees with the issues about Novo’s upcoming therapies, arguing the drugmaker has “among the finest pipelines within the business.” He pointed to Novo’s CagriSema, a drug candidate that targets GLP-1 and amylin, that Novo hopes will probably be accepted on the finish of this 12 months, and an experimental amylin-targeting drug known as zenagamtide that Novo has accelerated growth of, amongst different belongings.
“In fact, there’s a variety of issues in my pipeline that proper now I’ve the aware of look into and get excited (about) however not have shared it but with the world,” he stated. “So I’m extremely enthusiastic about our pipeline, and I’d simply say to the buyers who’re a bit bit skeptical, wait and see.”
Doustdar spoke to CNBC after the corporate stated its Wegovy capsule carried out higher than anticipated within the first quarter, and it raised its full-year revenue steerage.
